Asset Details
Do you wish to reserve the book?
Perception of Lemborexant Effectiveness as Assessed by the Patient Global Impression–Insomnia Questionnaire
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Perception of Lemborexant Effectiveness as Assessed by the Patient Global Impression–Insomnia Questionnaire
Do you wish to request the book?
Perception of Lemborexant Effectiveness as Assessed by the Patient Global Impression–Insomnia Questionnaire
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Perception of Lemborexant Effectiveness as Assessed by the Patient Global Impression–Insomnia Questionnaire
2025
Overview
Using data from a clinical study of lemborexant, evaluate responses to the Patient Global Impression-Insomnia (PGI-I) questionnaire, a simple 4-item questionnaire that assesses patients' perceptions of the effects of medication on sleep, which may help evaluate clinically meaningful changes from the patient's perspective.
Study E2006-G001-303, a 12-month, placebo (PBO)-controlled (first 6 months) Phase 3 study in adults with insomnia disorder, randomized subjects (1:1:1) to lemborexant 5 mg (LEM5; n=316), 10 mg (LEM10; n=315), or PBO (n=318). The second 6 months are not presented here. PGI-I results were analyzed post hoc in relation to patient-reported (subjective) sleep-onset latency (sSOL) and total-sleep-time (sTST).
At 6 months: 67.3% (LEM5) and 68.8% (LEM10) of subjects reported positive effects of medication helping them sleep versus 45.0% (both
<0.0001) with PBO. Positive effects on \"time to fall asleep\" were reported by 72.8% (LEM5) and 73.1% (LEM10) versus 46.1% with PBO (
<0.0001), and 58.0% (LEM5) and 62.0% (LEM10) reported positive effects on sleep duration versus 39.9% with PBO (
<0.0001). Subjects reporting positive effects on \"time to fall asleep\" had greater change from baseline (CFB; improvement) at 6 months in median sSOL (in minutes; LEM5= -26.8; LEM10= -32.1; PBO= -17.5;
<0.01) versus those reporting negative effects (LEM5= -9.1; LEM10= -10.4; PBO= -8.6; LEM5 vs PBO,
=0.52; LEM10 vs PBO,
=0.69). For sTST (in minutes) at 6 months, mean CFB tended to be greater for subjects reporting positive (LEM5=81.2, LEM10=93.2, PBO=74.8; LEM5 vs PBO,
=0.28; LEM10 vs PBO,
=0.18) versus negative (LEM5=46.4, LEM10=35.0, PBO=38.6; LEM5 vs PBO,
=0.44; LEM10 vs PBO,
=0.52) effects, although this was not statistically significant.
Patient impressions of the effects of lemborexant were positive based on the PGI-I and reflected improvements in subjective sleep outcome measures, indicating that the brief PGI-I tool may be useful in clinical practice.
Publisher
Dove Medical Press Limited,Dove Press,Dove,Dove Medical Press
